-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
CEN Biotech Inc. Announces Word Presto Partner Program
CEN Biotech Inc. Announces Word Presto Partner Program
WINDSOR, ON / ACCESSWIRE / November 8, 2022 / CEN Biotech Inc. ("CEN" or the "Company") (OTCQB:CENBF), a global holding company focused on the development of leading-edge digital media technologies, LED lighting technology and hemp-based products, is pleased to announce the formal launch of its Word Presto Partner Program for resellers and affiliates.
Word Presto is a product and a service that provides people with a customized web design experience coupled with affordable ongoing support and maintenance. To accompany our enterprise product and services, Word Presto has launched its Global Partner Program. This reseller program is designed for approved resellers and agencies to earn financial incentives for referring and selling the suite of Word Presto services.
Larry Lehoux, CEN's President and Chief Technology Officer, commented, "Our Word Presto Partner Program was aggressively designed to heavily compensate our business partners for their efforts in helping clients choose Word Presto for their website needs. All of the online sales are automatically tracked with an industry leading cookie that lasts for 60 days, as well as ongoing financial compensation for each sale that lasts for a year from the date of this initial purchase. We expect to have uptake in our offering from some targeted strategic partnerships in late 2022 and all throughout 2023."
You can learn more about the Word Presto partner offering by visiting the partner page located at
About CEN Biotech Inc.
CEN Biotech, Inc. is a global holding company focused on the development of digital media and LED lighting technology and hemp-based products. For further information on the Company, please visit our website at . Information about the Company can also be found on the Securities and Exchange Commission's (the "SEC") EDGAR site under the Issuer Profile of "CEN Biotech Inc."
Forward Looking Statements
This press release contains "forward-looking" statements. In particular, the words "believe," "may," "could," "should," "expect," "anticipate," "estimate," "project," "propose," "plan," "intend," and similar conditional words and expressions are intended to identify forward-looking statements. Any statements made in this press release about an action, event or development, are forward-looking. These forward-looking statements are only predictions and are subject to certain risks, uncertainties, and assumptions, many of which may be beyond the control of CEN, that could cause actual results to differ from those in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. Although CEN believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Potential risks include such factors as the inability to enter into agreements with parties with whom we are in discussions, factors that cannot be predicted with certainty, as well as additional risks and uncertainties that are identified and described in CEN's reports filed with the SEC. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. Actual results may differ materially from the forward-looking statements in this press release. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. CEN does not undertake, and it specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events or circumstances after the date of such statement except as required in accordance with applicable laws.
Press Contact
Brian S. Payne
Chief Executive Officer
CEN Biotech Inc.
Phone: (519) 981-0970
Email: brian@cenbiotechinc.com
Email: brian@nextrics.com
SOURCE: Cen Biotech, Inc.
View source version on accesswire.com:
WINDSOR, ON / ACCESSWIRE / November 8, 2022 / CEN Biotech Inc. ("CEN" or the "Company") (OTCQB:CENBF), a global holding company focused on the development of leading-edge digital media technologies, LED lighting technology and hemp-based products, is pleased to announce the formal launch of its Word Presto Partner Program for resellers and affiliates.
温莎,于/ACCESSWIRE/2022年11月8日/专注于开发前沿数字媒体技术、LED照明技术和基于大麻的产品的全球控股公司CEN Biotech Inc.(以下简称CEN或公司)(场外交易市场代码:CENBF)高兴地宣布,面向经销商和附属公司的Word Presto合作伙伴计划正式启动。
Word Presto is a product and a service that provides people with a customized web design experience coupled with affordable ongoing support and maintenance. To accompany our enterprise product and services, Word Presto has launched its Global Partner Program. This reseller program is designed for approved resellers and agencies to earn financial incentives for referring and selling the suite of Word Presto services.
Word Presto是一种产品和服务,为人们提供定制的网页设计体验,以及负担得起的持续支持和维护。为了配合我们的企业产品和服务,Word Presto推出了全球合作伙伴计划。此经销商计划专为经批准的经销商和代理机构设计,以获得推荐和销售Word Presto服务套件的财务奖励。
Larry Lehoux, CEN's President and Chief Technology Officer, commented, "Our Word Presto Partner Program was aggressively designed to heavily compensate our business partners for their efforts in helping clients choose Word Presto for their website needs. All of the online sales are automatically tracked with an industry leading cookie that lasts for 60 days, as well as ongoing financial compensation for each sale that lasts for a year from the date of this initial purchase. We expect to have uptake in our offering from some targeted strategic partnerships in late 2022 and all throughout 2023."
CEN首席技术官总裁兼首席技术官拉里·勒霍克斯表示:“我们的Word Presto合作伙伴计划旨在大力补偿我们的业务合作伙伴,因为他们帮助客户选择Word Presto以满足他们的网站需求。所有在线销售都会自动跟踪,持续60天的行业领先Cookie,以及从首次购买之日起持续一年的每笔销售的持续财务补偿。我们预计2022年底和整个2023年,我们的产品将从一些有针对性的战略合作伙伴那里获得收益。”
You can learn more about the Word Presto partner offering by visiting the partner page located at
您可以通过访问位于以下位置的合作伙伴页面了解更多有关Presto合作伙伴产品的信息
About CEN Biotech Inc.
关于CEN Biotech Inc.
CEN Biotech, Inc. is a global holding company focused on the development of digital media and LED lighting technology and hemp-based products. For further information on the Company, please visit our website at . Information about the Company can also be found on the Securities and Exchange Commission's (the "SEC") EDGAR site under the Issuer Profile of "CEN Biotech Inc."
CEN Biotech,Inc.是一家专注于数字媒体、LED照明技术和大麻产品开发的全球控股公司。欲了解更多有关该公司的信息,请访问我们的网站。有关该公司的信息也可以在证券交易委员会(“美国证券交易委员会”)的EDGAR网站上找到,该网站的发行者简介为“CEN Biotech Inc.”。
Forward Looking Statements
前瞻性陈述
This press release contains "forward-looking" statements. In particular, the words "believe," "may," "could," "should," "expect," "anticipate," "estimate," "project," "propose," "plan," "intend," and similar conditional words and expressions are intended to identify forward-looking statements. Any statements made in this press release about an action, event or development, are forward-looking. These forward-looking statements are only predictions and are subject to certain risks, uncertainties, and assumptions, many of which may be beyond the control of CEN, that could cause actual results to differ from those in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. Although CEN believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Potential risks include such factors as the inability to enter into agreements with parties with whom we are in discussions, factors that cannot be predicted with certainty, as well as additional risks and uncertainties that are identified and described in CEN's reports filed with the SEC. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. Actual results may differ materially from the forward-looking statements in this press release. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. CEN does not undertake, and it specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events or circumstances after the date of such statement except as required in accordance with applicable laws.
本新闻稿包含“前瞻性”声明。具体而言,“相信”、“可能”、“可能”、“应该”、“预期”、“预期”、“估计”、“项目”、“建议”、“计划”、“打算”以及类似的条件词汇和表述旨在识别前瞻性陈述。本新闻稿中关于行动、事件或发展的任何陈述都是前瞻性的。这些前瞻性陈述只是预测,受某些风险、不确定性和假设的影响,其中许多风险、不确定性和假设可能超出CEN的控制范围,可能导致实际结果与前瞻性陈述中的结果不同。因此,您不应过度依赖这些前瞻性陈述。尽管CEN认为前瞻性陈述中反映的预期是合理的,但它不能保证其前瞻性陈述将被证明是正确的。潜在风险包括无法与我们正在谈判的各方达成协议、无法确切预测的因素,以及在CEN提交给美国证券交易委员会的报告中确定和描述的其他风险和不确定性。请投资者注意,任何前瞻性陈述都不是对未来业绩的保证,实际结果或发展可能与预期的大不相同。实际结果可能与本新闻稿中的前瞻性陈述大不相同。本文中所作的陈述是截至本新闻稿发布之日的陈述,不应以任何后续日期为依据。除适用法律要求外,CEN不承担、也明确不承担更新任何前瞻性陈述以反映此类陈述日期后发生的事件、事态发展、事件或情况的任何义务。
Press Contact
压接点
Brian S. Payne
Chief Executive Officer
CEN Biotech Inc.
Phone: (519) 981-0970
Email: brian@cenbiotechinc.com
Email: brian@nextrics.com
布莱恩·S·佩恩
首席执行官
CEN生物技术公司
电话:(519)981-0970
电子邮件:Brian@cenBiotechinc.com
电子邮件:brian@nex ics.com
SOURCE: Cen Biotech, Inc.
资料来源:CEN生物技术公司
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧